Moderna seeks vaccine approval for adolescents
US-based biotech company Moderna is applying for the use of its Covid-19 vaccine for adolescents aged 12 to 17 in Switzerland, it said on Friday.
This content was published on June 11, 2021 - 18:02Its vaccine is currently approved only for people aged 18 and over. So far, only Pfizer/BioNTech has been authorised by approvals authority Swissmedic to administer the vaccine to people over 12.
Swissmedic, the Swiss Agency for Therapeutic Products, said in a statement also on Friday that it is analysing the data submitted to it, including a large ongoing clinical trial being conducted on young people aged 12 and over.
The institute will decide on the Moderna application as soon as it has sufficient evidence of the safety, efficacy and quality of this vaccine against Covid-19 in this age group.
The vaccination rollout in Switzerland has accelerated, reaching between 60,000-90,000 jabs a day. Over 5.8 million Covid-19 doses were administered between late December and June 9. Over 25% of the population are fully vaccinated.
Comments under this article have been turned off. You can find an overview of ongoing debates with our journalists here. Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.